RNA, U7 small nuclear 97 pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU7-97P profile across patient tissues and cancer cell-line models. RNU7-97P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNU7-97P is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, RNU7-97P RNA expression shows 6,747 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BRCA, and STAD as cancer lineages where RNU7-97P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-97P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-97P survival associations across molecular data types. RNU7-97P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-97P RNA expression–survival associations across cancer types. High RNU7-97P expression shows unfavorable associations in UVM, LIHC, BRCA, COAD, LGG and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RNU7-97P RNA expression.
This table summarizes RNU7-97P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-97P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-97P shows lower tumor expression in BRCA and KICH and higher tumor expression in LUAD and LIHC. The BRCA box plot shows higher RNU7-97P RNA expression in normal versus tumor tissue (log2 FC = −1.194, t-test p < 0.001).
This table shows molecular features associated with RNU7-97P in patient tissues and cancer cell lines. In patient samples, RNU7-97P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
